```html

Granulomatosis with Polyangiitis (GPA) – A Comprehensive Medical Guide

Overview

Granulomatosis with Polyangiitis (GPA), previously known as Wegener’s granulomatosis, is a rare, autoimmune vasculitis that primarily attacks small‑ and medium‑sized blood vessels. The inflammation produces necrotizing granulomas—clusters of immune cells that can destroy tissue—in the respiratory tract and kidneys, but virtually any organ system may be involved.

• Incidence: Approximately 3 – 4 new cases per million adults each year in the United States and Europe.<sup>1</sup>
• Prevalence: About 20 – 30 cases per million people worldwide.<sup>2</sup>
• Age & gender: Most diagnoses occur between ages 40‑65; men are slightly more frequently affected than women (≈1.2:1).<sup>3</sup>

Because GPA can progress rapidly and affect vital organs, early recognition and treatment are crucial to prevent irreversible damage.

Symptoms

Symptoms vary depending on which organs are involved, but they generally fall into three classic categories: upper airway, lower airway, and renal. Below is a comprehensive list.

Upper Respiratory Tract

• Chronic sinusitis – persistent congestion, facial pain, or worsening sinus infections.
• Nasal crusting or ulceration – often painless but can cause bleeding.
• Ear involvement – hearing loss, ear pain, or recurrent otitis media.
• Oral ulcerations – especially on the palate or gums.

Lower Respiratory Tract

• Cough – dry or productive.
• Shortness of breath – may be progressive.
• Hemoptysis – coughing up blood, ranging from streaks to significant amounts.
• Chest pain – often pleuritic (sharp with breathing).
• Pulmonary nodules or infiltrates – detectable on imaging, can cavitate.

Kidney (Renal) Manifestations

• Hematuria – blood in the urine, often microscopic at first.
• Proteinuria – excess protein in urine, signaling glomerulonephritis.
• Rapidly progressive renal failure – rising creatinine, reduced urine output.

Other Organ Systems

• Skin – palpable purpura, livedo reticularis, or ulcerative lesions.
• Eyes – scleritis, conjunctivitis, or orbital inflammation causing pain and redness.
• Peripheral nerves – mononeuritis multiplex (patchy numbness/weakness).
• Joint pain – arthralgias without swelling are common.
• General symptoms – fever, fatigue, weight loss, and night sweats.

Causes and Risk Factors

The exact trigger for GPA is unknown, but research points to an interplay of genetic susceptibility, environmental exposures, and an aberrant immune response.

Genetic Factors

• Variants in the HLA‑DPB1 and HLA‑DQB1 genes increase risk.<sup>4</sup>
• Family clustering is rare, suggesting genetics play a modest role.

Environmental Triggers

• Silica dust exposure (e.g., mining, construction) has been linked to higher incidence.<sup>5</sup>
• Chronic infections (e.g., Staphylococcus aureus colonization) may precipitate disease flares.
• Drugs – rare cases associated with medications such as propylthiouracil or cocaine.

Immune Factors

• Presence of antineutrophil cytoplasmic antibodies (ANCA), especially c‑ANCA (proteinase‑3 ANCA), in >90 % of patients with active disease.<sup>6</sup>
• Abnormal activation of neutrophils that adhere to vessel walls, releasing enzymes that damage tissue.

Who Is at Higher Risk?

• Adults aged 40‑65, with a slight male predominance.
• Individuals with occupational silica exposure.
• People who are chronic carriers of Staphylococcus aureus in the nose.
• Those with a family history of other autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus).

Diagnosis

Diagnosing GPA requires a combination of clinical suspicion, laboratory testing, imaging, and often a tissue biopsy.

Laboratory Tests

• ANCA testing – c‑ANCA (PR3‑ANCA) positivity is highly suggestive; p‑ANCA (MPO‑ANCA) may be present in a minority.
• Complete blood count (CBC) – may show anemia or leukocytosis.
• Renal panel – creatinine, urea, and electrolytes assess kidney function.
• Urinalysis – detects hematuria, proteinuria, or red‑cell casts.
• Erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP) – elevated in active disease.

Imaging Studies

• Chest X‑ray or CT scan – reveals nodules, cavitations, or diffuse infiltrates.
• Sinus CT – assesses chronic sinusitis, bone erosion, or mucosal thickening.
• Kidney ultrasound – useful for evaluating size and cortical thickness.

Biopsy

A definitive diagnosis often hinges on histopathology:

• Upper airway or lung tissue – shows necrotizing granulomas with vasculitis.
• Kidney biopsy – demonstrates pauci‑immune crescentic glomerulonephritis (little immune complex deposition).

Because GPA can mimic infections or malignancy, obtaining a specimen helps rule out other causes.

Classification Criteria

The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) criteria assign points for:

• Positive PR3‑ANCA (+5 points)
• Upper airway involvement (+2)
• Renal involvement (+3)
• Imaging findings consistent with GPA (+2)

A total score ≥5 classifies a patient as having GPA with a specificity >95 %.

Treatment Options

Therapy aims to induce remission quickly, then maintain it with a lower‑dose regimen. Modern protocols have greatly improved survival—from < 25 % in the 1950s to > 80 % 5‑year survival today.<sup>7</sup>

Induction Therapy (to achieve remission)

• High‑dose glucocorticoids – e.g., prednisone 1 mg/kg/day (often 40–60 mg) tapered over 4–6 months.
• Combination immunosuppressants (choose one):
  • Rituximab (375 mg/m² weekly × 4 weeks or 1 g bi‑weekly × 2) – now preferred for many patients.
  • Cyclophosphamide (intravenous 15 mg/kg every 2–3 weeks or oral 2 mg/kg/day) – useful when rapid control is needed.
  • In rare, refractory cases: methotrexate or mycophenolate mofetil.

Maintenance Therapy (to keep disease quiet)

• Rituximab – 500 mg every 6 months for 2–5 years.
• Azathioprine – 2–2.5 mg/kg/day.
• Mycophenolate mofetil – 1–1.5 g twice daily.
• Low‑dose glucocorticoids (≤10 mg prednisone daily) are usually continued for the first 12 months.

Adjunctive Measures

• Trimethoprim‑sulfamethoxazole (TMP‑SMX) – reduces risk of Staphylococcus aureus–related relapses, especially in patients with nasal carriage.
• Prophylaxis for Pneumocystis jirovecii pneumonia (PJP) when using cyclophosphamide or high‑dose steroids.
• Vaccinations (influenza, pneumococcal, COVID‑19) given when disease is quiescent.

Lifestyle & Supportive Care

• Smoking cessation – smoking worsens lung involvement.
• Balanced diet rich in calcium and vitamin D to counter steroid‑induced bone loss.
• Regular exercise to maintain muscle strength and reduce cardiovascular risk.
• Psychological support – chronic disease can cause anxiety and depression; counseling or support groups are beneficial.

Living with Granulomatosis with Polyangiitis

GPA is a chronic condition, but many patients lead active, fulfilling lives with proper management.

Daily Management Tips

1. Medication adherence – set alarms, use pill organizers, and keep a medication log.
2. Regular monitoring – blood tests every 1‑3 months initially, then every 6 months; urine analysis for renal involvement.
3. Self‑examination – watch for new sinus symptoms, hematuria, cough, or skin lesions and report promptly.
4. Protect your kidneys – stay hydrated, avoid NSAIDs unless prescribed, and monitor blood pressure.
5. Eye care – annual ophthalmology exams if you have ocular involvement.
6. Vaccination schedule – maintain up‑to‑date immunizations; avoid live vaccines while on high‑dose immunosuppression.
7. Travel planning – carry a copy of your medication list, ensure access to medical care, and consider prophylactic antibiotics if traveling to high‑risk areas.

Psychosocial Aspects

• Connect with patient advocacy groups such as the Vasculitis Foundation.
• Consider a care coordinator or nurse practitioner familiar with vasculitis.
• Mind‑body practices (yoga, meditation) can help manage stress, which may trigger flares.

Prevention

Because the exact cause is unclear, primary prevention is limited. However, risk reduction strategies include:

• Reduce silica exposure – use protective equipment if you work in construction, sandblasting, or mining.
• Eliminate nasal Staphylococcus aureus colonization – some clinicians use mupirocin nasal ointment for chronic carriers.
• Prompt treatment of sinus infections – reduces chronic inflammation that may trigger vasculitis.
• Healthy lifestyle – smoking cessation, balanced diet, and regular exercise lower overall inflammatory burden.

Complications

If left untreated or poorly controlled, GPA can cause serious, potentially irreversible damage:

• Kidney failure – may require dialysis or transplantation.
• Permanent lung damage – fibrosis, cavitary lesions, or chronic respiratory insufficiency.
• Upper airway destruction – saddle‑nose deformity, chronic sinusitis, or hearing loss.
• Vision loss – from scleritis or orbital inflammation.
• Peripheral neuropathy – can lead to lasting weakness or sensory loss.
• Infection – immunosuppressive therapy increases susceptibility to bacterial, viral, and fungal infections.
• Secondary malignancies – especially bladder cancer with long‑term cyclophosphamide use.
• Cardiovascular disease – chronic inflammation accelerates atherosclerosis.

When to Seek Emergency Care

References

1. Jennette JC, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatol. 2013;65(1):1‑11.
2. Harzallah K, et al. Epidemiology of ANCA‑Associated Vasculitis. Curr Opin Rheumatol. 2020;32(1):48‑56.
3. Stegemann J, et al. Incidence and prevalence of granulomatosis with polyangiitis. Rheumatology. 2021;60(3):1189‑1195.
4. Pomales A, et al. Genetic susceptibility loci in ANCA‑associated vasculitis. Nat Commun. 2022;13:2079.
5. Stolt P, et al. Silica exposure and risk of granulomatosis with polyangiitis. Occup Environ Med. 2019;76(3):208‑214.
6. Helwig EL, et al. ANCA testing and clinical significance. Clin Lab Med. 2020;40(2):277‑295.
7. Walsh M, et al. Long‑term outcomes of GPA treated with rituximab versus cyclophosphamide. N Engl J Med. 2023;388:123‑134.

```